Literature DB >> 146747

Antigens associated with acute leukemia detected in the primed lymphocyte test.

N L Reinsmoen, J H Kersey, E J Yunis.   

Abstract

Mixed lymphocyte culture (MLC) studies of families with several leukemia patients, all potential bone marrow transplant recipients, demonstrated that cells from acute myelogenous leukemia patients (5 of 5) and acute undifferentiated leukemia patients (1 of 4) in relapse stimulated autologous lymphocytes as well as lymphocytes from siblings known to be identical at the major histocompatibility linkage group. In the patients studied, the blast transformation induced by leukemia cells was not detectable when the patient was in remission. Stimulation by leukemia cells also elicited increased responses of the lymphocytes from normal haploidentical siblings, parents, and unrelated individuals as compared to stimulation by normal allogeneic cells or leukemia cells of patients with leukemia in remission. The primed lymphocyte test (PLT) was used successfully to establish HLA-D identity of the leukemia patients and their respective HLA-identical siblings, despite high percentages of circulatory blasts. Utilizing lymphocytes from normal siblings primed against the leukocytes from an HLA-identical sibling with leukemia, we also presented results of PLT's which suggested that the stimulation induced by leukemia cells in MLC was produced by leukemia-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 146747     DOI: 10.1093/jnci/60.3.537

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Autologous responses to human leukaemic cells in mixed leucocyte culture.

Authors:  L K Ashman; D E O'Keefe; C A Juttner; I R Toogood; M S Rice
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Lack of correlation between lymphocyte activating determinants and HLA-DR on acute leukaemias.

Authors:  G M Taylor; J C Ridway; W D Fergusson; R Harris
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.